GT Biopharma Faces Delisting Concerns
Ticker: GTBP · Form: 8-K · Filed: Nov 27, 2024 · CIK: 109657
| Field | Detail |
|---|---|
| Company | Gt Biopharma, INC. (GTBP) |
| Form Type | 8-K |
| Filed Date | Nov 27, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $2,500,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
GT Biopharma's 8-K signals potential delisting issues.
AI Summary
GT Biopharma, Inc. filed an 8-K on November 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, previously known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/, is incorporated in Delaware and has its principal executive offices in San Francisco, California.
Why It Matters
This filing indicates potential issues with GT Biopharma's continued listing on an exchange, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading and investor confidence.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
- November 21, 2024 (date) — Date of earliest event reported
- November 27, 2024 (date) — Filing Date
FAQ
What specific listing rule or standard has GT Biopharma, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that GT Biopharma, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the primary reason for the potential delisting of GT Biopharma, Inc. shares?
The filing is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard,' indicating the company is at risk of being removed from its stock exchange due to not meeting ongoing requirements.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 21, 2024.
What is GT Biopharma, Inc.'s state of incorporation?
GT Biopharma, Inc. is incorporated in Delaware.
Has GT Biopharma, Inc. operated under any previous names?
Yes, GT Biopharma, Inc. has previously operated under the names OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.
Filing Stats: 638 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2024-11-27 16:05:18
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
- $2,500,000 — ockholders' equity has fallen below the $2,500,000 required minimum for continued listing
Filing Documents
- form8-k.htm (8-K) — 33KB
- 0001493152-24-047994.txt ( ) — 196KB
- gtbp-20241121.xsd (EX-101.SCH) — 3KB
- gtbp-20241121_lab.xml (EX-101.LAB) — 33KB
- gtbp-20241121_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: November 27, 2024 By: /s/ Alan Urban Alan Urban Chief Financial Officer